Search

Displaying results 1761 - 1770 of 3015 in total
  1. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.

  2. Drug

    Resiquimod

    go.drugbank.com/drugs/DB06530
    Investigational

    When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.

  3. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.

  4. Drug

    Oxybenzone

    go.drugbank.com/drugs/DB01428
    Approved

    Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because...

    Mixtures: Super CC Color-Corection Care All Over Blur Stick, Help Me Broad Spectrum SPF 30 Sunscreen Retinol Day Treatment Lotion
  5. Target

    Proton-coupled folate transporter

    go.drugbank.com/bio_entities/BE0001048
    TransporterTargetHumans

    Also acts as a lower-affinity, pH-independent heme carrier protein and constitutes the main importer of heme in the intestine (PubMed:17156779). … Hence, participates in the trafficking of heme and increases intracellular iron content (PubMed:32621820)

    Synonyms: Heme carrier protein 1
  6. Drug

    EI-1071

    go.drugbank.com/drugs/DB18486
    Investigational

    EI-1071 is a selective Colony Stimulating Factor-1 Receptor kinase inhibitor.

  7. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

  8. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    FDA approved on July 31, 2009.

  9. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    [L39105] It was subsequently approved by the FDA in March 2024.[L50622] … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.

  10. Drug

    Cyclosporine

    go.drugbank.com/drugs/DB00091
    ApprovedInvestigationalVet approved

    [A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]